Austin Regional Clinic to begin COVID-19 vaccine trial

Austin Regional Clinic recently began recruiting for a COVID-19 vaccine clinical trial set to begin this month. In this interview on KVUE News, Director of ARC Clinical Research Jeff Repper said the study offers participants an opportunity to be a part of history and benefit humankind.

“It is the top priority of the US and the world to find a successful vaccine to prevent the infection and spread of COVID-19,” said Dr. Gretchen Crook, principal investigator for ARC Clinical Research. “This vaccine candidate has the potential to save lives and allow us to return to a way of life that will restore our economy, re-connect our friendships, and continue activities we all enjoy.”

COVID-19 Vaccine Trial

ARC is seeking 250 volunteers from across Central Texas to enroll in this late phase clinical trial. The trial is open to healthy adults between age 18 and 85. People who have had a known positive case of COVID-19 or who are immunocompromised are not eligible to participate.

“There are 7 billion people in our world who will need access to a vaccine to prevent COVID-19 infection and ARC Clinical Research is thrilled to have a role in bringing a vaccine to Americans,” said Repper.

Tags: COVID-19 vaccine trial, KVUE News

More on this Topic

Tell me about your day.

“I’m a physician; we always look at the medical perspective, but there’s more to it,” says Dr. Natalie A. Williams, Family Medicine at Austin Regional Clinic when discussing “whole patient care” in this recent episode of ARC DocTalk on KVUE-TV.

ARC Clinical Research starts to enroll children 12-17 years old for COVID-19 Vaccine Trial

ARC Clinical Research, ARC’s medical research department that enables clinical trials, announces it looks to enroll children 12-17 years old in Pfizer’s COVID-19 vaccine clinical trial that began in early August 2020.

ARC COVID-19 vaccine trial to continue on schedule

In response to announcements of the possible release of a COVID-19 vaccine as early as October 2020, ARC has said it will continue its vaccine trial. Dr. Anas Daghestani, CEO of ARC has said, “Our timeline is still the same.”